Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 22nd Annual Global Investment Conference
Verrica Pharmaceuticals (VRCA) announced that CEO Ted White will present a business overview at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Verrica Pharmaceuticals (VRCA) announced that CEO Ted White will present a business overview at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 2:00 p.m. ET. The conference will be held virtually, and attendees can access the live webcast on Verrica's website. The company is developing VP-102, a potential first-in-class therapy for molluscum contagiosum, for which an NDA was submitted in September 2019. A Complete Response Letter from the FDA was received on July 13, 2020, regarding this NDA.
Positive
- VP-102 has potential to be the first-in-class topical therapy for molluscum contagiosum.
- Company completed a Phase 2 study of VP-102 for common warts and is conducting another Phase 2 study for external genital warts.
Negative
- Received a Complete Response Letter from the FDA regarding the NDA for VP-102 on July 13, 2020.
Details
News Market Reaction – VRCA
The recorded move for VRCA in the trading session of this news was +3.67%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WEST CHESTER, Pa., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will present a business overview at the H.C. Wainwright 22nd Annual Global Investment Conference, taking place virtually on Tuesday, September 15, 2020, at 2:00 p.m. ET.
A live webcast of the event can be accessed in the Investors/Presentations & Events section of the Verrica website at http://www.verrica.com. The webcast replay will be available shortly after conclusion of the event for 30 days.
About Verrica Pharmaceuticals Inc.
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. The Company’s late-stage product candidate, VP-102, is a potential first-in-class topical therapy for the treatment of molluscum contagiosum. Verrica submitted an NDA for VP-102 for the treatment of molluscum in September 2019. A Complete Response Letter was received from the FDA regarding the NDA for VP-102 on July 13, 2020. If approved, VP-102 will be marketed in the United States under the conditionally accepted brand name YCANTH™. In addition, Verrica has successfully completed a Phase 2 study of VP-102 for the treatment of common warts and is currently conducting a Phase 2 study of VP-102 for the treatment of external genital warts. The Company is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. For more information, visit www.verrica.com.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.